GlassScriptPhysician profile
Nader Kamangar
NPI 1922093285
$1,986.77
in general payments reported to CMS, 2019-2025
22 companies · $833 in 2025
The $833 reported for 2025 was more than what 75% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $84.15 · 2022: $13.68 · 2023: $263 · 2024: $395 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.54 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $308.34 | 2019-2025 | |
| Amgen INC. | $210.21 | 2023-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $199.53 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $187.12 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.63 | 2023-2025 | Ofev |
| United Therapeutics Corporation | $159.03 | 2024-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $132.19 | 2019-2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $130.49 | 2019-2024 | Xarelto |
| La Jolla Pharmaceutical Company | $54.75 | 2019 | |
| Glaxosmithkline, LLC. | $53.24 | 2025 | Nucala |
| Gilead Sciences, INC. | $50.80 | 2019-2022 | |
| Medtronic, INC. | $49.37 | 2025 | Illumisite |
| Philips North America LLC | $43.26 | 2023-2025 | Vest Therapy Und |
| Viatris Specialty LLC | $41.78 | 2025 | Yupelri |
| Atos Medical INC | $35.80 | 2024 | Provox Life Home Hme |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $34.69 | 2023 | Hillrom - Life 2000 Ventilation System |
| Astellas Pharma US INC | $33.46 | 2023 | Cresemba |
| Olympus America INC. | $30.39 | 2023 | Evis Exera III Bronchovideoscope |
| Nabriva Therapeutics, Plc | $24.79 | 2020 | |
| Genentech USA, INC. | $22.80 | 2019 | |
| Mylan Specialty L.P. | $22.10 | 2024 | Yupelri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Kamangar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.